These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6117304)

  • 1. Nadolol in human serum and breast milk.
    Devlin RG; Duchin KL; Fleiss PM
    Br J Clin Pharmacol; 1981 Sep; 12(3):393-6. PubMed ID: 6117304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of nadolol by patients with renal impairment.
    Herrera J; Vukovich RA; Griffith DL
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):227S-231S. PubMed ID: 37878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
    Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
    PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nadolol binding to human serum proteins.
    Patel L; Johnson A; Turner P
    J Pharm Pharmacol; 1984 Jun; 36(6):414-5. PubMed ID: 6146679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic studies in patients with nadolol: oral and intravenous administration.
    Dreyfuss J; Brannick LJ; Vukovich RA; Shaw JM; Willard DA
    J Clin Pharmacol; 1977; 17(5-6):300-7. PubMed ID: 16040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nadolol in hypertensive patients maintained on long-term hemodialysis.
    Michaels RS; Duchin KL; Akbar S; Meister J; Levin NW
    Am Heart J; 1984 Oct; 108(4 Pt 2):1091-4. PubMed ID: 6148869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary Iodine Sufficiency and Moderate Insufficiency in the Lactating Mother and Nursing Infant: A Computational Perspective.
    Fisher W; Wang J; George NI; Gearhart JM; McLanahan ED
    PLoS One; 2016; 11(3):e0149300. PubMed ID: 26930410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of orally coadministered nadolol and its deuterated analogue in human serum and urine by gas chromatography with selected-ion monitoring mass spectrometry.
    Cohen AI; Devlin RG; Ivashkiv E; Funke PT; McCormick T
    J Pharm Sci; 1984 Nov; 73(11):1571-5. PubMed ID: 6151597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nadolol beta-blockade on blood pressure in hypertension.
    Duchin KL; Vukovich RA; Dennick LG; Groel JT; Willard DA
    Clin Pharmacol Ther; 1980 Jan; 27(1):57-63. PubMed ID: 6101312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.
    Jack DB; Kendall MJ; Dean S; Laugher SJ; Zaman R; Tenneson ME
    Biopharm Drug Dispos; 1982; 3(1):47-54. PubMed ID: 6123352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nadolol: placental transfer and excretion in the milk of rats.
    Dreyfuss J; Shaw JM; Miller TJ
    Toxicol Appl Pharmacol; 1977 Feb; 39(2):275-82. PubMed ID: 15333
    [No Abstract]   [Full Text] [Related]  

  • 12. Nadolol in thyrotoxicosis.
    Peden NR; Isles TE; Stevenson IH; Crooks J
    Br J Clin Pharmacol; 1982 Jun; 13(6):835-40. PubMed ID: 6124267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of nadolol in healthy subjects.
    Schäfer-Korting M; Bach N; Knauf H; Mutschler E
    Eur J Clin Pharmacol; 1984; 26(1):125-7. PubMed ID: 6714285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadolol and propranolol in the treatment of hypertension: a double-blind comparison.
    El Mehairy MM; Shaker A; Ramadan M; Hamza S; Tadros SS
    J Int Med Res; 1980; 8(3):193-8. PubMed ID: 6104614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.
    Dreyfuss J; Griffith DL; Singhvi SM; Shaw JM; Ross JJ; Vukovich RA; Willard DA
    J Clin Pharmacol; 1979; 19(11-12):712-20. PubMed ID: 43870
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacology and clinical pharmacokinetics of nadolol].
    Lazowski J; Wegrzyn B; Lypka A
    Pol Tyg Lek; 1981 Sep; 36(39):1521-4. PubMed ID: 6121320
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhancement of nadolol elimination by activated charcoal and antibiotics.
    du Souich P; Caillé G; Larochelle P
    Clin Pharmacol Ther; 1983 May; 33(5):585-90. PubMed ID: 6839631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding.
    Naito T; Kubono N; Deguchi S; Sugihara M; Itoh H; Kanayama N; Kawakami J
    J Hum Lact; 2015 May; 31(2):301-6. PubMed ID: 25447596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of low-dose nadolol for ventricular arrhythmias.
    Morganroth J; Duchin KL
    Am J Cardiol; 1986 Aug; 58(3):273-8. PubMed ID: 3739916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.
    Selen A; Kinkel AW; Darke AC; Greene DS; Welling PG
    Eur J Clin Pharmacol; 1986; 30(6):699-704. PubMed ID: 2876899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.